A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies
Latest Information Update: 28 May 2024
Price :
$35 *
At a glance
- Drugs Cabotegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 28 May 2024 New trial record